For the U.K. pharmaceutical industry, a Brexit risks causing uncertainty and creating barriers to investment. “It’s vital the U.K. remains engaged in the EU to influence legislative and regulatory policy developments affecting the life sciences ecosystem,” says the BioIndustry Association, a U.K. industry organization. Ninety life sciences firms have stated publicly that the U.K. should stay in the EU.
Additionally, if the U.K. votes to Brexit, two European pharmaceutical institutions currently based in London—the European Medicines Agency and a part of the EU’s planned unitary patent system—would have to relocate to an EU country.I believe the EMA is basically the EU's version of the FDA. The German pharma sector calling for them to leave (and relocate to Berlin?) already.
I was also surprised to learn that good ol' Paul Hodges (Captain of the DOOOOOOOOOOOOOOOOOOM team) was actually voting Remain. Huh.
I presume there are a raft of people who have Marie Curie Fellowships and the like, who may face some trouble? Readers, your thoughts?